AMPLITUDE VASCULAR SYSTEMS acquired by STRYKER
Context
Stryker has completed the acquisition of Amplitude Vascular Systems, a private medical device company, which develops a next-generation intravascular lithotripsy (IVL) platform, designed to treat complex peripheral arterial disease, this acquisition represents a significant milestone in the expansion of Stryker's peripheral vascular portfolio, by integrating Amplitude Vascular Systems' innovative technology, which uses carbon dioxide-generated pressure waves, to optimize arterial diameter, while minimizing damage and improving deliverability, treatment speed, and therapeutic efficacy, with the goal of strengthening Stryker's position in peripheral vascular solutions, by offering solutions for physicians and patients, to treat cardiovascular disease, Stryker's strategy is to develop its portfolio of products and services, to improve patient and healthcare outcomes, by offering innovative and integrated solutions, for physicians, hospitals, and patients, financial and legal advisory services were provided by reputable consulting firms, to ensure the success of the operation
AMPLITUDE VASCULAR SYSTEMS, which reported an EBITDA margin of in 2026, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (14.3x).
-> Deep-dive in Healthcare & Pharma market trends
Target
Amplitude Vascular Systems is a medical device company based in Boston, Massachusetts, focused on treating severely calcified peripheral arterial disease, offering a next-generation intravascular lithotripsy (IVL) platform designed to treat complex peripheral arterial disease, with a business model based on selling innovative medical devices, such as the Pulse System, which uses carbon dioxide-generated pressure waves to optimize arterial diameter, while minimizing damage and improving deliverability, treatment speed, and therapeutic efficacy, with an experienced management team, including Hitinder Gurm, M.D., interventional cardiologist and chief medical officer, and Robert Chisena, Ph.D., chief technical officer, founded in 2017, with the support of global investors, including BioStar Capital, Cue Growth Partners, and others, to address the needs of patients and physicians in the treatment of cardiovascular disease
Ent. Value
Equity Value
Multiples
EV / Revenue
EV / EBITDA
EV / EBIT
Historical Financials (USD)
Similar deals in Life Sciences
| Date | Acquirer | Target | Country | Sector |
|---|---|---|---|---|
| 06/2026 | CORDENPHARMA | AMBIOPHARM | UNITED STATES | CDMO |
| 06/2026 | DHCARE | OTTOBOCK HUMAN MOBILITY | GERMANY | Medical Devices |
| 04/2026 | ASTORG | THERMO FISHER MICROBIOLOGY | UNITED STATES | Diagnostic Equipment |
| 04/2026 | AMERICAN INDUSTRIAL PARTNERS AIP | AVANOS MEDICAL | UNITED STATES | Medical Consumables |
| 04/2026 | Gilead Sciences | Arcellx | UNITED STATES | R&D Biotech |
| 04/2026 | VITREX MEDICAL GROUP | HERNIAMESH | ITALY | Implants & Prosthetics |
| 04/2026 | REVENIO GROUP CORPORATION | VISIONIX INTERNATIONAL | FRANCE | Diagnostic Equipment |
| 04/2026 | FINE FOODS & PHARMACEUTICALS | SOFAR | ITALY | CDMO |
| 04/2026 | UCB | NEURONA THERAPEUTICS | UNITED STATES | R&D Biotech |
| 04/2026 | OURY MEDICAL | CÉFIMÉCA | FRANCE | Implants & Prosthetics |
REFERENCES
Valuation range: EV 500M - 1.5b USD
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of AMPLITUDE VASCULAR SYSTEMS by STRYKER are reserved for mynth community members. Register for free to unlock full data.
Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.
Press release: view release
Target: amplitude vascular systems
Acquirer: stryker